Institution
University of Oklahoma
Education•Norman, Oklahoma, United States•
About: University of Oklahoma is a education organization based out in Norman, Oklahoma, United States. It is known for research contribution in the topics: Population & Radar. The organization has 25269 authors who have published 52609 publications receiving 1821706 citations. The organization is also known as: OU & Oklahoma University.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this article, the authors reported the observation of the X(3872) in the J/psipi(+)pi(-) channel with decaying to mu(+)mu(-), in p (p) over bar collisions at roots=1.96 TeV.
Abstract: We report the observation of the X(3872) in the J/psipi(+)pi(-) channel, with J/psi decaying to mu(+)mu(-), in p (p) over bar collisions at roots=1.96 TeV. Using approximately 230 pb(-1) of data collected with the Run II D0 detector, we observe 522+/-100 X(3872) candidates. The mass difference between the X(3872) state and the J/psi is measured to be 774.9+/-3.1(stat)+/-3.0(syst) MeV/c(2). We have investigated the production and decay characteristics of the X(3872) and find them to be similar to those of the psi(2S) state.
418 citations
••
University of Oklahoma1, Oklahoma Medical Research Foundation2, University of Paris-Sud3, University Hospitals Birmingham NHS Foundation Trust4, Queen Elizabeth II Hospital5, Linköping University6, Uppsala University7, University of Bergen8, Stavanger University Hospital9, Cincinnati Children's Hospital Medical Center10, Veterans Health Administration11, Karolinska Institutet12, Örebro University13, King's College London14, University of Colorado Denver15, University of Minnesota16, Carolinas Medical Center17, Harvard University18, Washington University in St. Louis19, National Institutes of Health20, Hannover Medical School21, University of Adelaide22, Newcastle University23, Del Rosario University24
TL;DR: The results highlight the importance of genes that are involved in both innate and adaptive immunity in Sjögren's syndrome, including TNFAIP3, PTTG1, PRDM1, DGKQ, FCGR2A, IRAK1BP1, ITSN2 and PHIP, among others.
Abstract: Sjogren's syndrome is a common autoimmune disease (affecting ∼0.7% of European Americans) that typically presents as keratoconjunctivitis sicca and xerostomia. Here we report results of a large-scale association study of Sjogren's syndrome. In addition to strong association within the human leukocyte antigen (HLA) region at 6p21 (Pmeta = 7.65 × 10(-114)), we establish associations with IRF5-TNPO3 (Pmeta = 2.73 × 10(-19)), STAT4 (Pmeta = 6.80 × 10(-15)), IL12A (Pmeta = 1.17 × 10(-10)), FAM167A-BLK (Pmeta = 4.97 × 10(-10)), DDX6-CXCR5 (Pmeta = 1.10 × 10(-8)) and TNIP1 (Pmeta = 3.30 × 10(-8)). We also observed suggestive associations (Pmeta < 5 × 10(-5)) with variants in 29 other regions, including TNFAIP3, PTTG1, PRDM1, DGKQ, FCGR2A, IRAK1BP1, ITSN2 and PHIP, among others. These results highlight the importance of genes that are involved in both innate and adaptive immunity in Sjogren's syndrome.
417 citations
••
TL;DR: The ATLAS trigger system as discussed by the authors selects events by rapidly identifying signatures of muon, electron, photon, tau lepton, jet, and B meson candidates, as well as using global event signatures, such as missing transverse energy.
Abstract: Proton-proton collisions at root s = 7 TeV and heavy ion collisions at root(NN)-N-s = 2.76 TeV were produced by the LHC and recorded using the ATLAS experiment's trigger system in 2010. The LHC is designed with a maximum bunch crossing rate of 40 MHz and the ATLAS trigger system is designed to record approximately 200 of these per second. The trigger system selects events by rapidly identifying signatures of muon, electron, photon, tau lepton, jet, and B meson candidates, as well as using global event signatures, such as missing transverse energy. An overview of the ATLAS trigger system, the evolution of the system during 2010 and the performance of the trigger system components and selections based on the 2010 collision data are shown. A brief outline of plans for the trigger system in 2011 is presented.
417 citations
••
TL;DR: The study of 32, 5- and 6- person groups supports the belief that interpretation underlies information sharing and is necessary for favorable decision outcomes and supports the proposed negative effect of low social presence media on interpretation in terms of depth of information sharing.
Abstract: Research on information sharing has viewed this activity as essential for informing groups on content relevant to a decision. We propose and examine an alternate function of information sharing, i.e., the social construction of meaning. To accomplish this goal, we turn to social construction, social presence, and task closure theories. Drawing from these theories, we hypothesize relationships among the meeting environment, breadth and depth of information shared during a meeting, and decision quality. We explore these relationships in terms of the effects of both the media environment in which the group is situated and the medium that group memberschoose to utilize for their communication.Our study of 32, 5- and 6-person groups supports our belief that interpretation underlies information sharing and is necessary for favorable decision outcomes. It also supports the proposed negative effect of low social presence media on interpretation in terms of depth of information sharing; a low social presence medium, however, promotes information sharing breadth. Finally, the findings indicate that when in multimedia environments and faced with a relatively complex task,choosing to utilize an electronic medium facilitates closure and, therefore, favorable outcomes.
415 citations
••
University of Texas MD Anderson Cancer Center1, Gynecologic Oncology Group2, University of Cincinnati3, Memorial Sloan Kettering Cancer Center4, Johns Hopkins University5, University of Oklahoma6, Samsung Medical Center7, Saitama Medical University8, University of California, Irvine9, Ohio State University10, University of Colorado Denver11, Fox Chase Cancer Center12, Palo Alto Medical Foundation13
TL;DR: The roles of secondary surgical cytoreduction and bevacizumab in this population of women with ovarian cancer with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer, and a clinical complete response to primary platinum-based chemotherapy were explored.
Abstract: Summary Background Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here. Methods The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre). Eligible patients were adult women (aged ≥18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer, and a clinical complete response to primary platinum-based chemotherapy, who had been disease-free for at least 6 months following last infused cycle of platinum. Patients were randomly assigned (1:1) to standard chemotherapy (six 3-weekly cycles of paclitaxel [175 mg/m 2 of body surface area] and carboplatin [area under the curve 5]) or the same chemotherapy regimen plus bevacizumab (15 mg/kg of bodyweight) every 3 weeks and continued as maintenance every 3 weeks until disease progression or unacceptable toxicity. Individuals who participated in both the bevacizumab objective and surgical objective (which is ongoing) were randomly assigned (1:1:1:1) to receive either of these two chemotherapy regimens with or without prior secondary cytoreductive surgery. Randomisation for the bevacizumab objective was stratified by treatment-free interval and participation in the surgical objective. The primary endpoint was overall survival, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00565851. Findings Between Dec 10, 2007, and Aug 26, 2011, 674 women were enrolled and randomly assigned to standard chemotherapy (n=337) or chemotherapy plus bevacizumab (n=377). Median follow-up at the end of the trial on Nov 5, 2014, was 49·6 months in each treatment group (IQR 41·5–62·2 for chemotherapy plus bevacizumab; IQR 40·8–59·3 for chemotherapy), at which point 415 patients had died (214 in the chemotherapy group and 201 in the chemotherapy plus bevacizumab group). Based on pretreatment stratification data, median overall survival in the chemotherapy plus bevacizumab group was 42·2 months (95% CI 37·7–46·2) versus 37·3 months (32·6–39·7) in the chemotherapy group (hazard ratio [HR] 0·829; 95% CI 0·683–1·005; p=0·056). We identified incorrect treatment-free interval stratification data for 45 (7%) patients (equally balanced between treatment groups); a sensitivity analysis of overall survival based on the audited treatment-free interval stratification data gave an adjusted HR of 0·823 (95% CI 0·680–0·996; p=0·0447). In the safety population (all patients who initiated treatment), 317 (96%) of 325 patients in the chemotherapy plus bevacizumab group had at least one grade 3 or worse adverse event compared with 282 (86%) of 332 in the chemotherapy group; the most frequently reported of these in the chemotherapy plus bevacizumab group compared with the chemotherapy group were hypertension (39 [12%] vs two [1%]), fatigue (27 [8%] vs eight [2%]), and proteinuria (27 [8%] vs none). Two (1%) treatment-related deaths occurred in the chemotherapy group (infection [n=1] and myelodysplastic syndrome [n=1]) compared with nine (3%) in the chemotherapy plus bevacizumab group (infection [n=1], febrile neutropenia [n=1], myelodysplastic syndrome [n=1], secondary malignancy [n=1]; deaths not classified with CTCAE terms: disease progression [n=3], sudden death [n=1], and not specified [n=1]). Interpretation The addition of bevacizumab to standard chemotherapy, followed by maintenance therapy until progression, improved the median overall survival in patients with platinum-sensitive recurrent ovarian cancer. Although the intention-to-treat analysis for overall survival was not significant, our sensitivity analysis based on corrected treatment-free interval stratification indicates that this strategy might be an important addition to the therapeutic armamentarium in these patients. Funding National Cancer Institute and Genentech.
414 citations
Authors
Showing all 25490 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ronald C. Kessler | 274 | 1332 | 328983 |
Michael A. Strauss | 185 | 1688 | 208506 |
Derek R. Lovley | 168 | 582 | 95315 |
Ashok Kumar | 151 | 5654 | 164086 |
Peter J. Schwartz | 147 | 647 | 107695 |
Peter Buchholz | 143 | 1181 | 92101 |
Robert Hirosky | 139 | 1697 | 106626 |
Elizabeth Barrett-Connor | 138 | 793 | 73241 |
Brad Abbott | 137 | 1566 | 98604 |
Lihong V. Wang | 136 | 1118 | 72482 |
Itsuo Nakano | 135 | 1539 | 97905 |
Phillip Gutierrez | 133 | 1391 | 96205 |
P. Skubic | 133 | 1573 | 97343 |
Elizaveta Shabalina | 133 | 1421 | 92273 |
Richard Brenner | 133 | 1108 | 87426 |